GnRH-antagonist class (degarelix, cetrorelix, ganirelix, relugolix, elagolix)

The GnRH-antagonist class is the modern hormonal-therapy backbone across four clinical settings whose pharmacology converges on the same receptor and diverges on the practical use case. The historical arc moves from injectable peptides for narrow specialty-medicine indications in the late 1990s and 2000s to oral small molecules reshaping ambulatory hormonal therapy for advanced prostate cancer and endometriosis in the 2020s. The class is one of the cleanest worked examples on the site of how receptor pharmacology, pharmacokinetic engineering, and clinical-development strategy compound across two decades to produce a therapeutic category that practitioners now use in operationally different ways than the parent class permitted a generation ago.

Cetrorelix (Cetrotide, Serono / EMD Serono) was the first GnRH antagonist to reach the US market, approved 11 August 2000 for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. The clinical problem cetrorelix solved is the timing problem in IVF: ovarian-stimulation regimens using gonadotropin injections (FSH, hMG) to drive multiple-follicle development carry an intrinsic risk that the rising estradiol from the developing follicle cohort will trigger an endogenous LH surge before oocyte retrieval, causing premature ovulation and loss of the cycle. The pre-antagonist approach used long-acting GnRH-agonist downregulation across multiple weeks before stimulation; the antagonist approach allows GnRH-receptor block to be initiated mid-stimulation (typically around stimulation day 5–7), achieves LH-surge prevention within hours, and shortens the overall protocol by 1–2 weeks. Cetrorelix is dosed as either daily subcutaneous 0.25 mg injections through the stimulation phase or a single 3 mg subcutaneous depot dose covering approximately 96 hours of receptor block.

Ganirelix (Antagon, Organon — also marketed as Orgalutran) was approved 29 July 1999 — slightly preceding cetrorelix in US regulatory timing — for the same controlled-ovarian-stimulation indication. The molecule is dosed as 0.25 mg daily subcutaneous injections during the ovarian-stimulation phase. The two daily-injection IVF antagonists have not separated cleanly in head-to-head outcome comparisons across pregnancy-rate, ovarian-hyperstimulation-syndrome-incidence, or live-birth-rate endpoints, and prescribing choice typically reflects formulary availability, injection-device preference, and prescriber familiarity rather than evidence-based differentiation. The class-level effect — flare-free, rapid GnRH-receptor block compatible with mid-stimulation initiation, eliminating the premature-LH-surge risk that had constrained IVF protocols since the 1980s — is the operational benefit that has made antagonist-protocol IVF the dominant approach in modern reproductive medicine for most patient populations.

Degarelix (Firmagon, Ferring Pharmaceuticals) was approved 24 December 2008 for advanced prostate cancer, on the basis of the CS21 trial (Klotz, Boccon-Gibod, Shore et al., BJU International 2008, 102:1531–1538), a 12-month phase 3 randomised open-label parallel-group trial that allocated 610 men with hormone-naïve adenocarcinoma of the prostate 1:1:1 to degarelix 240 mg subcutaneous loading followed by monthly 80 mg maintenance, degarelix 240 mg loading followed by monthly 160 mg maintenance, or leuprolide 7.5 mg monthly intramuscular depot. The primary endpoint — testosterone suppression below 50 ng/dL maintained between days 28 and 364 — was met by greater than 96% of patients across all three arms, demonstrating non-inferiority of the antagonist for the standard-of-care castration endpoint. The decisive secondary-endpoint difference was the time to castration: 96% of degarelix patients reached castrate testosterone by day 3, versus 0% of leuprolide patients, who had instead experienced the expected agonist-class testosterone flare during the first 1–2 weeks. The flare-avoidance benefit anchored the clinical case for degarelix in patient populations where the agonist-class flare is itself a clinical concern — particularly metastatic disease with spinal-cord-compression-vulnerable bone metastases, where the brief agonist-flare surge in testosterone can precipitate neurological emergency, and patients with significant lower-urinary-tract obstruction where flare-driven tumour-volume increase can precipitate urinary retention. The approved adult dosing is a 240 mg subcutaneous loading dose split between two 120 mg injections at initiation, followed by 80 mg subcutaneous maintenance dosing every 28 days.

Relugolix (Orgovyx, Myovant Sciences / Sumitomo Pharma) was approved 18 December 2020 as the first oral GnRH-receptor antagonist for advanced prostate cancer, on the basis of the HERO trial (Shore, Saad, Cookson et al., N Engl J Med 2020, 382:2187–2196). HERO was an open-label phase 3 randomised trial that allocated 934 men with advanced prostate cancer 2:1 to relugolix 360 mg oral loading dose on day 1 followed by 120 mg daily oral maintenance (n=622) or leuprolide 22.5 mg intramuscular depot every 3 months (n=308), for 48 weeks. The primary endpoint of sustained testosterone suppression below 50 ng/dL from day 29 through week 48 was met by 96.7% of relugolix patients versus 88.8% of leuprolide patients (difference 7.9 percentage points; the formal superiority claim was met). The rapid-castration secondary endpoint was characteristic of the antagonist class: 56.0% of relugolix patients reached castrate testosterone by day 4 versus 0% of leuprolide patients, with the 4-day relugolix castration rate reflecting the difference between oral-loading-dose receptor block and the agonist-class flare. The testosterone-recovery secondary endpoint — assessed in a prespecified 184-patient subset followed for 90 days after treatment discontinuation — showed cumulative testosterone recovery to greater than 280 ng/dL in 54% of relugolix patients versus 3.2% of leuprolide patients, with mean 90-day post-discontinuation testosterone of 288 ng/dL on relugolix versus 59 ng/dL on leuprolide — a difference that reflects the directly-acting, washout-dependent antagonist pharmacology versus the depot-driven and downregulation-mediated agonist pharmacology, and that has substantial implications for patients receiving androgen-deprivation therapy as an adjuvant or neoadjuvant intervention with an explicit treatment-cessation timeline rather than as palliative therapy.

The HERO cardiovascular finding is the most-discussed and most-contested data point in modern GnRH-antagonist pharmacology. Major adverse cardiovascular events (MACE: cardiac ischaemic event, cerebrovascular event, or cardiovascular death) occurred in 2.9% of relugolix patients and 6.2% of leuprolide patients across the 48-week treatment window, corresponding to a hazard ratio of 0.46. The trial was not powered for the cardiovascular endpoint, the comparison is a secondary safety analysis rather than a prespecified primary efficacy outcome, and the mechanistic interpretation — whether GnRH agonism through the agonist class confers cardiovascular risk via a receptor-level pathway, or whether the antagonist class confers cardiovascular protection — remains a hypothesis-generating observation rather than a confirmed comparative-effectiveness finding. The FDA Orgovyx label reflects the as-yet-unconfirmed nature of the cardiovascular comparative claim. The clinical-practice impact has been substantial regardless: the cardiovascular signal has shifted the conversation about ADT selection in men with significant baseline cardiovascular disease toward the antagonist class, while the broader oncology community has acknowledged that a confirmatory cardiovascular outcomes trial — the PRONOUNCE study, which sought to test the cardiovascular hypothesis directly — was terminated early for slow accrual and did not produce a definitive answer, leaving the HERO secondary endpoint as the most credible available evidence on the question.

Elagolix (Orilissa, AbbVie) was approved 23 July 2018 as the first oral GnRH-receptor antagonist for endometriosis-associated pain, on the basis of the replicate Elaris EM-I and Elaris EM-II trials (Taylor, Giudice, Lessey et al., N Engl J Med 2017, 377:28–40). The two parallel double-blind randomised 6-month phase 3 trials enrolled 872 women in EM-I and 817 women in EM-II, allocating patients across three arms: elagolix 150 mg once daily, elagolix 200 mg twice daily, or placebo. The co-primary endpoints — proportion of women achieving clinical response in dysmenorrhoea and non-menstrual pelvic pain at month 3 — were met in both trials at both elagolix doses, with the higher dose producing larger response rates: dysmenorrhoea response 46.4% (low dose) and 75.8% (high dose) versus 19.6% (placebo) in EM-I; 43.4% and 72.4% versus 22.7% in EM-II. Non-menstrual pelvic pain response was 50.4% and 54.5% versus 36.5% (EM-I) and 49.8% and 57.8% versus 36.5% (EM-II). The dose-dependence reflects the partial-suppression pharmacology: the low dose preserves more residual estrogen and produces clinically meaningful but submaximal endometriosis-pain reduction; the high dose drives deeper estrogen suppression with proportionally greater pain reduction but at the cost of greater hypoestrogenic adverse-event burden. The FDA-approved treatment durations reflect that trade-off: 150 mg once daily is approved for up to 24 months; 200 mg twice daily is limited to 6 months, with the duration ceiling driven by bone-mineral-density loss and the hepatic-transaminase elevation rate that is dose-dependent.

The Oriahnn (elagolix-estradiol-norethindrone, AbbVie) fixed-dose combination was approved 29 May 2020 for heavy menstrual bleeding associated with uterine fibroids in premenopausal women, on the basis of the replicate Elaris UF-I and Elaris UF-II trials (Schlaff, Ackerman, Al-Hendy et al., N Engl J Med 2020, 382:328–340). The two phase 3 double-blind randomised 6-month trials enrolled 412 women (UF-I) and 378 women (UF-II), evaluating elagolix 300 mg twice daily with add-back estradiol 1 mg and norethindrone acetate 0.5 mg once daily versus placebo. The primary endpoint — menstrual blood loss below 80 mL per cycle and at least 50% reduction from baseline at the final month — was met by 68.5% in UF-I and 76.5% in UF-II on elagolix-plus-add-back versus 8.7% and 10.0% on placebo. The add-back hormone-replacement component is the mechanistic distinction from Orilissa: at the higher elagolix dose required for fibroid-bleeding control, the bone-mineral-density and hypoestrogenic-symptom burden of monotherapy exceed the acceptable safety profile for chronic dosing, and the add-back estradiol-norethindrone offsets the hypogonadal adverse events while permitting the elagolix-driven suppression of menstrual blood loss to be maintained. The FDA-labelled treatment duration is 24 months.

The Myfembree (relugolix-estradiol-norethindrone, Myovant / Pfizer) fixed-dose combination occupies the same therapeutic space as Oriahnn but with relugolix as the GnRH-antagonist component. Myfembree received FDA approval 26 May 2021 for heavy menstrual bleeding associated with uterine fibroids and 5 August 2022 for moderate-to-severe pain associated with endometriosis. The molecular composition is relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg in a single once-daily oral tablet — the practical advantage versus the Oriahnn split-pill regimen is the convenience of a single daily tablet versus the Oriahnn morning-and-evening dosing pattern. The clinical-development case for Myfembree in both fibroid and endometriosis indications rests on the LIBERTY-1, LIBERTY-2, and LIBERTY-extension trials (fibroids) and the SPIRIT-1 and SPIRIT-2 trials (endometriosis), which demonstrated significant reductions in menstrual blood loss and endometriosis pain respectively across the 24-week and 52-week treatment windows, with bone-mineral-density loss limited to less than 1% from baseline at 12 months on the fixed-dose combination, an improvement over the BMD trajectory observed with antagonist monotherapy.

The class fits within the broader pharmacology landscape covered on the peptide receptor pharmacology atlas — the GnRH receptor is a Class A GPCR, mechanistically distinct from the Class B GPCRs (PTHR1, GLP-1R, GIP-R, glucagon-R, GHRH-R) that anchor much of the modern peptide-therapeutic catalog. The hormonal-therapy framing for advanced prostate cancer extends into the andropause and peptides dossier, and the post-cessation testosterone-recovery question intersects with the TRT discontinuation playbook. The female reproductive-medicine framing extends into the PCOS and peptides dossier and the female sexual dysfunction beyond Vyleesi dossier. The forward-link to the planned prostate cancer hormonal therapy and peptides dossier and the existing pregnancy-lactation peptide safety registry covers the indication-specific safety considerations. The WADA prohibited-status registry covers the sport-doping framing.